Clinical Trials / Research Studies

Neurofibromatosis NF2

NF110: Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110)

• Ages: 6 Years and older

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 c ...More

SEL-TH-1601: Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

PURPOSE: In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor. The researchers are asking patients with NF2 related tumors to be in the study, because their he ...More